A coronary sinus reducer (CSR), a small hourglass-shaped device implanted near the heart through keyhole surgery, has demonstrated effectiveness in treating refractory angina, a severe form of heart disease that remains problematic despite medication and surgery. The device works by narrowing a vein at the back of the heart to redirect blood flow to oxygen-deprived areas of the heart muscle.
A comprehensive study examining 491 patients with refractory angina between 2014 and 2024 found that the implant produced significant reductions in chest pain in 75% of recipients within six months. The research, conducted across 19 hospitals in England and Scotland, involved 474 patients who received the implant. Most patients returned home either the day of the procedure or the following day, with serious complications occurring rarely.
Refractory angina affects an estimated 300,000 people in England, yet only a small number have received this treatment, which costs the NHS £11,400 per device. Patient outcomes have been notable, with individuals reporting substantial improvements in quality of life, increased physical activity tolerance, and reduced anxiety associated with the condition. One patient noted being able to exercise more freely and climb stairs without fear of triggering attacks, compared to previously experiencing five attacks weekly.
Despite the promising results, medical experts indicate that additional trials are necessary before the device becomes standard treatment for refractory angina. NHS funding approval would be required to expand access to the implant. Medical professionals have characterized the findings as reassuring regarding both safety and clinical effectiveness in routine practice, offering hope for patients living with this debilitating cardiac condition.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI